Richard Paxman: Paxman Scalp Cooling has carried out a directed issue of 1.9 million new shares
Richard Paxman, Chief Medical Officer and Managing Director at Paxman, shared a post on LinkedIn:
“Paxman Scalp Cooling has carried out a directed issue of 1.9 million new shares, raising proceeds of SEK 123.5 million.
This has been a week to remember. I am delighted to announce we have just raised 123.5 MSEK (£9.4m) through a directed issue. We welcome and thank our new investors including Eiffel Investment Group and Unionen amongst others and thank a number of our existing shareholders ALCUR Fonder, Andra AP-Fonden, Aktia Asset Management and SEB Asset Management for their continued support in ensuring we achieve our vision supporting patients no matter where they are in the world to access our technology to manage chemotherapy induced side effects.
This welcomed investment will support the accelerated commercialization of our device to prevent chemotherapy induced peripheral neuropathy, invest in to a new state of the art facility to support our growth and further R and D, specifically topical interventions to support improved efficacy of scalp cooling with new and novel therapies.
Thank you Carnegie Investment Bank and Delphi for your support with this deal.
So grateful for all our team for making this work! We have the ability to help so many patients and their families globally and together we can do this.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023